Evidence map›Paper›PMID 24434522›Full record

ArticleCell death & disease2014

Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons.

A M Dolga, A de Andrade, L Meissner, H-G Knaus, M Höllerhage, P Christophersen, H Zischka, N Plesnila, G U Höglinger, C Culmsee

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 76 citations in OpenAlex.

  1. SK3 channel and mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Frontiers in neuroscience · 2025
    Article
  8. Article
  9. Article
  10. The raphe nuclei are the early lesion site of gastricActa pharmaceutica Sinica. B · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. CaMolecules (Basel, Switzerland) · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

A M DolgaInstitut für Pharmakologie und Klinische Pharmazie, Fachbereich Pharmazie, Philipps-Universität Marburg, Marburg, Germany.
A de AndradeExperimental Neurology, Philipps-Universität Marburg, Marburg, Germany.
L MeissnerInstitute of Stroke and Dementia Research, University of Munich Medical School, Munich, Germany.
H-G KnausDepartment for Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
M Höllerhage1] Experimental Neurology, Philipps-Universität Marburg, Marburg, Germany [2] German Center for Neurodegenerative Diseases (DZNE), Munich, Germany [3] Department of Neurology, Technical University Munich, Munich, Germany.
P ChristophersenAniona, Ballerup, Denmark.
H ZischkaInstitute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
N PlesnilaInstitute of Stroke and Dementia Research, University of Munich Medical School, Munich, Germany.
G U Höglinger1] Experimental Neurology, Philipps-Universität Marburg, Marburg, Germany [2] German Center for Neurodegenerative Diseases (DZNE), Munich, Germany [3] Department of Neurology, Technical University Munich, Munich, Germany.
C CulmseeInstitut für Pharmakologie und Klinische Pharmazie, Fachbereich Pharmazie, Philipps-Universität Marburg, Marburg, Germany.
Philipps University of Marburg · DEGerman Center for Neurodegenerative Diseases · DEHelmholtz Zentrum München · DEInnsbruck Medical University · ATSaniona (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small-conductance Ca(2+)-activated K(+) channel activation is an emerging therapeutic approach for treatment of neurological diseases, including stroke, amyotrophic lateral sclerosis and schizophrenia. Our previous studies showed that activation of SK channels exerted neuroprotective effects through inhibition of NMDAR-mediated excitotoxicity. In this study, we tested the therapeutic potential of SK channel activation of NS309 (25 μM) in cultured human postmitotic dopaminergic neurons in vitro conditionally immortalized and differentiated from human fetal mesencephalic cells. Quantitative RT-PCR and western blotting analysis showed that differentiated dopaminergic neurons expressed low levels of SK2 channels and high levels of SK1 and SK3 channels. Further, protein analysis of subcellular fractions revealed expression of SK2 channel subtype in mitochondrial-enriched fraction. Mitochondrial complex I inhibitor rotenone (0.5 μM) disrupted the dendritic network of human dopaminergic neurons and induced neuronal death. SK channel activation reduced mitochondrial membrane potential, while it preserved the dendritic network, cell viability and ATP levels after rotenone challenge. Mitochondrial dysfunction and delayed dopaminergic cell death were prevented by increasing and/or stabilizing SK channel activity. Overall, our findings show that activation of SK channels provides protective effects in human dopaminergic neurons, likely via activation of both membrane and mitochondrial SK channels. Thus, SK channels are promising therapeutic targets for neurodegenerative disorders such as Parkinson's disease, where dopaminergic cell loss is associated with progression of the disease.

Indexed as

CalciumCell DifferentiationDopaminergic NeuronsHumansMembrane Potential, MitochondrialMitochondrial MembranesNeuroprotective AgentsParkinson DiseaseProtein TransportSmall-Conductance Calcium-Activated Potassium ChannelsCalciumKCNN1 protein, humanKCNN2 protein, humanKCNN3 protein, humanNeuroprotective AgentsSmall-Conductance Calcium-Activated Potassium Channels

Identifiers

PMID24434522
PMCPMC4040692
OpenAlexW2012070790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.